3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
22
Triple Negative Breast Neoplasms
9
Lung Neoplasms
8
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Pancreatic Ductal
2
Biliary Tract Neoplasms
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Salivary Gland Neoplasms
1
Rhabdomyosarcoma
1
Resectable Pancreatic Cancer
1
Pancreatic Adenocarcinoma
1
Osteosarcoma
1
Non-Small Cell Lung Cancer Metastatic
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasms, Basal Cell
1
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anal Cancer Metastatic
×
Albumin-Bound Paclitaxel
×
90 days
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled